Back to News
Market Impact: 0.4
FDA Approves GSK's Hibsago For Chronic Hepatitis B In Adults Without Cirrhosis
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
The FDA approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in adults, to be used in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy. The article excerpt provides no sales, patient-population, or market-reaction figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
GSK0.85
More News
- FDA approves GSK’s Hibsago for chronic hepatitis B treatment
- GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says
- CSL names Deborah Waterhouse as new chief executive
- New Mexico took on Meta alone and won a $25 billion judgment over Facebook’s privacy violations
- Meta ordered to pay $25 billion in case related to Cambridge Analytica scandal
- Judge orders Meta to pay $25bn in fines for Facebook privacy violations
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements
- AI Tools for Independent Research Firms: A Publishing System